alectinib
alectinib
Overview
Alectinib is a targeted anticancer therapy used primarily in ALK receptor tyrosine kinase–positive non-small-cell lung cancer (NSCLC). It is a second-generation ALK inhibitor designed to suppress oncogenic signaling driven by ALK rearrangements, a molecular subtype that defines a clinically important subset of lung cancers. By inhibiting ALK signaling, alectinib helps reduce tumor cell proliferation and disease progression in ALK-positive malignancies.
Clinically, alectinib has become an important treatment option in both advanced and resected early-stage ALK-positive NSCLC. Recent research continues to evaluate its comparative effectiveness, resistance mechanisms, toxicity profile, and potential interactions with immune and cellular pathways such as PD-1/PD-L1 signaling, cancer-associated fibroblasts, and autophagy-related processes.
Focus of Latest Publications
Recent publications on alectinib have focused on its role in ALK-positive non-small cell lung cancer across treatment settings, from early-stage adjuvant therapy to postoperative recurrence and resistance biology. In the randomized ALINA trial exploratory analysis, investigators examined whether the disease-free survival benefit of adjuvant alectinib versus chemotherapy was consistent across surgical characteristic subgroups and when patients were reclassified by AJCC/UICC 8th edition staging. Separate cost-effectiveness analyses compared adjuvant alectinib with platinum-based chemotherapy in the United States and first-line alectinib with lorlatinib in Italy, reflecting continued interest in the clinical and economic positioning of alectinib within ALK-targeted treatment strategies.
Several studies addressed outcomes after surgery or recurrence. A retrospective multicenter series of patients with postoperative recurrent ALK-rearranged lung adenocarcinoma reported durable efficacy with first-line alectinib after recurrence, with median progression-free survival not reached and a 5-year PFS rate of 58.3%, alongside acceptable safety. These findings support the use of alectinib as a targeted option in the recurrent setting, although the authors noted that prospective studies are needed to define the optimal timing of ALK-TKI initiation.
Other recent work examined alectinib in mechanistic and translational contexts. One study using in-vitro non-small cell lung cancer models compared growth and drug-response models under conditions with and without alectinib and cancer-associated fibroblasts, finding that alectinib altered competitive dynamics and promoted competitive exclusion, whereas cancer-associated fibroblasts favored coexistence of resistant and sensitive cells. Another study investigated alectinib-induced toxicity and identified liver-originated selective autophagic degradation of BTD as a mechanism underlying concurrent hepatotoxicity and dermatotoxicity; systemic biotin deficiency was implicated, and biotin supplementation mitigated both toxicities in the reported model.
Resistance-related research also linked alectinib to immune and signaling changes in ALK-rearranged NSCLC. In a study of gilteritinib, the authors reported that gilteritinib could overcome alectinib resistance, inhibit ALK protein levels, and suppress PD-L1 and CD8 co-expression in cell and animal models. Together, these publications portray alectinib as a central ALK-targeted therapy with ongoing relevance in efficacy, resistance, toxicity, and health-economic evaluations.